ANAB Anaptysbio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANAB

Price (delayed)

$52.02

Market cap

$1.51B

P/E Ratio

N/A

Dividend/share

$20.51

EPS

-$0.94

Enterprise value

$1.54B

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 57

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients ...

Highlights
The company's gross profit has surged by 108% YoY
ANAB's revenue has soared by 108% YoY
ANAB's EPS has dropped by 104% since the previous quarter but it has surged by 80% year-on-year
The net income has shrunk by 102% QoQ but it has soared by 81% YoY
Anaptysbio's equity has plunged by 66% from the previous quarter and by 63% YoY
The company's quick ratio fell by 16% QoQ and by 8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.anaptysbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ANAB

ANAB stock price

How has the Anaptysbio stock price performed over time
Intraday
1.52%
1 week
-8.77%
1 month
-25.45%
1 year
144.57%
YTD
7.3%
QTD
-6.2%

Financial performance

How have Anaptysbio's revenue and profit performed over time
Revenue
$232.39M
Gross profit
$232.39M
Operating income
$40.8M
Net income
-$26.79M
Gross margin
100%
Net margin
-11.5%
ANAB's operating income has surged by 141% year-on-year but it is down by 15% since the previous quarter
The company's operating margin has surged by 120% YoY but it fell by 14% QoQ
The company's gross profit has surged by 108% YoY
ANAB's revenue has soared by 108% YoY

Price vs fundamentals

How does ANAB's price correlate with its fundamentals

Growth

What is Anaptysbio's growth rate over time

Valuation

What is Anaptysbio stock price valuation
P/E
N/A
P/B
117.32
P/S
6.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.64
ANAB's EPS has dropped by 104% since the previous quarter but it has surged by 80% year-on-year
Anaptysbio's equity has plunged by 66% from the previous quarter and by 63% YoY
ANAB's revenue has soared by 108% YoY
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 28.6 but 9% more than its last 4 quarters average of 5.8

Efficiency

How efficient is Anaptysbio business performance
The return on invested capital has dropped by 142% since the previous quarter but it has surged by 73% year-on-year
The ROA has shrunk by 117% QoQ but it has soared by 75% YoY
ANAB's return on sales has dropped by 105% since the previous quarter but it has surged by 91% year-on-year

Dividends

What is ANAB's dividend history
DPS
$20.51
Dividend yield
39.43%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Anaptysbio financials performed over time
The total assets is 4% more than the total liabilities
The total assets has contracted by 22% YoY and by 10% from the previous quarter
The company's total liabilities fell by 18% YoY and by 3.1% QoQ
ANAB's debt to equity has surged by 179% since the previous quarter and by 114% year-on-year
Anaptysbio's equity has plunged by 66% from the previous quarter and by 63% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.